DNMT3A and acute myeloid leukemia: Given the emerging evidence for Oct1 in HSPCs and leukemic transformation and Oct2 in activating TLR-mediated inflammatory signaling in myeloid cells, this putative miR-196b/Oct1/2 signaling axis could be an important ‘switch’ in controlling HSPC cell fate upon acquisition of AML driver mutations such as DNMT3A. Altogether, our data indicate miR-196b is a pivotal and pleiotropic regulator of myeloid leukemogenesis.